OPKO Health, Inc. (NASDAQ:OPK - Free Report) - HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for shares of OPKO Health in a report released on Monday, March 3rd. HC Wainwright analyst Y. Chen now anticipates that the biotechnology company will post earnings per share of ($0.08) for the quarter, down from their previous forecast of ($0.07). HC Wainwright has a "Buy" rating and a $3.00 price objective on the stock. The consensus estimate for OPKO Health's current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health's Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.31) EPS.
OPK has been the topic of a number of other research reports. StockNews.com upgraded OPKO Health from a "sell" rating to a "hold" rating in a research report on Monday, March 3rd. Barrington Research reaffirmed an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a report on Friday, February 28th.
Check Out Our Latest Research Report on OPKO Health
OPKO Health Price Performance
NASDAQ:OPK traded up $0.01 during trading hours on Thursday, hitting $1.90. The stock had a trading volume of 5,853,623 shares, compared to its average volume of 4,711,948. The company has a 50 day simple moving average of $1.58 and a two-hundred day simple moving average of $1.56. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -10.00 and a beta of 1.63. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health has a one year low of $0.86 and a one year high of $2.04.
OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.09. The company had revenue of $183.60 million during the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the business. FMR LLC grew its holdings in shares of OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 11,089 shares during the last quarter. Orion Portfolio Solutions LLC bought a new position in shares of OPKO Health during the third quarter valued at about $45,000. Cibc World Markets Corp bought a new position in shares of OPKO Health during the fourth quarter valued at about $45,000. Zacks Investment Management purchased a new position in shares of OPKO Health in the fourth quarter worth about $49,000. Finally, Ieq Capital LLC bought a new stake in shares of OPKO Health in the 4th quarter valued at about $52,000. 64.63% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at OPKO Health
In other news, CEO Phillip Md Et Al Frost bought 500,000 shares of the company's stock in a transaction that occurred on Wednesday, December 11th. The stock was bought at an average price of $1.56 per share, for a total transaction of $780,000.00. Following the transaction, the chief executive officer now directly owns 212,411,477 shares of the company's stock, valued at $331,361,904.12. This represents a 0.24 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have purchased 1,389,971 shares of company stock valued at $2,124,442 in the last quarter. Insiders own 47.26% of the company's stock.
OPKO Health Company Profile
(
Get Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Further Reading
Before you consider OPKO Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OPKO Health wasn't on the list.
While OPKO Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
